US equities |
MU $936.91 ▼-1.71% NVDA $223.22 ▼-2.32% AAPL $345.75 ▲+1.31% SPCX $153.83 ▼-1.73% META $742.94 ▼-2.57% TSLA $368.08 ▼-1.90% SNDK $1,427.01 ▼-3.73% AMD $581.21 ▼-4.02%
FinancialContent

IDEAYA Biosciences, Inc. - Common Stock (NQ:IDYA)

34.04 -0.22 (-0.64%)
Delayed Quote Updated: 11:21 AM EDT, Oct 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about IDEAYA Biosciences, Inc. - Common Stock

News headline image
A Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in Oncology
From USA News Group
Via GlobeNewswire
News headline image
Biocytogen Announces IDEAYA’s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise
From Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Via Business Wire
News headline image
MarketBeat Week in Review – 7/15 - 7/19
Stocks took a breather to close the week, but corporate earnings and the next reading on the PCE index will help determine what direction the market moves next 
Via MarketBeat
Topics Economy
News headline image
Positive News is Driving This Cancer Drug Maker’s Stock Higher
IDEAYA Biosciences stock is up more than 16% on positive treatment data in a Phase 2 clinical trial, but after a 76% run-up, IDYA stock may need a breather 
Via MarketBeat
IDEAYA Biosciences Inc. (NASDAQ: IDYA) is a Stock Spotlight on 1/24
Via Investor Brand Network
IDEAYA Biosciences Inc. (NASDAQ: IDYA) is a Stock Spotlight on 1/19
Via Investor Brand Network
Ideaya Biosciences Inc. (NASDAQ: IDYA) is a Stock Spotlight on 5/11
Via Investor Brand Network
IDEAYA Biosciences Inc. (NASDAQ: IDYA) Leading the Way in Monday Trading Based on Percentage Gain
Via Investor Brand Network
IDEAYA Biosciences Inc. (NASDAQ: IDYA) Featured in Virtual Coverage of the 34th Annual Roth Conference
Via Investor Brand Network